|
Day Two: Friday, November 17, 2006
7:45 am Morning Coffee
(Breakfast Workshop Sponsorship Available)
8:15 Chairperson’s Opening
Remarks
| Interactive Panel |
8:30 Partnership and Outsourcing Deals in India: Successes and Failures
• Overcoming cultural differences and infrastructure obstacles
• Key cost drivers and less obvious budgetary pitfalls
• Choosing a worthy partner and performing capability assessment
• Making the most of your partnerships
• Addressing IP concerns and ensuring patent protection
• Training staff and transferring technology
• Effectively controlling quality
Facilitator:
Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs,
WW Licensing & External Research, Merck & Co., Inc.
Panelists:
Suresh Katti, Ph.D., Principal Scientist, Chemistry & Structural
Biology, Bayer
Kamesh Venugopal, President, North America, Torrent Pharma
Fidela Moreno, M.D., Senior Director, Global Development Operations, Asia and Latin America, Amgen, Inc.
Dr. Debra Sponholtz , Director, Business Development, ChemBiotek
Research Intl.
|
9:30 Coffee Break
(Sponsorship Available)
|
|
10:15 Outsourcing Strategy for India: The Why, the What, and the How
• A model for conducting research in India today...and tomorrow
• Logistical challenges in transferring technology, transferring data, and training
staff
• Integrating efforts in India with all other worldwide research activities
Daniel Warner, Strategic External Resourcing (SER), Novartis Institutes for BioMedical Research
(NIBR)
|
|
|
11:00 Strategies for Successful Outsourcing of Chemistry to India
M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.
|
11:45 Translational Medicine in India: Update from a Cohort Study in a Major Chronic Disease
• Cohort study design and objectives
• Status of bio-analytics capabilities in India
• Patient enrollment and study retention
• Business model and study design to address ethics and privacy issues
• Government policy considerations
• Future prospects for “translational medicine” in India
Gene Williams, Chief Executive Officer, Cambridge Healthtech Associates
Sudhir Borgonha, M.D., Chief Executive Officer, Translational
Medicine India
12:30 Luncheon Workshop or Lunch on Own (Sponsorship Available)
| Interactive Panel |
2:00 Collaborative Research Efforts in India Opportunities and Challenges
• Overcoming technical and scientific difficulties in international research and
development projects
• Understanding cultural differences and their impact on science and business
exchanges
• Strategies to deal with a lack of resources during projects
• Establishing relationships and communicating effectively in a cross-cultural global
collaboration
• Clarifying issues around acceptance of data from India by US/EU agencies
Facilitator:
Rakesh Dixit, Ph.D., DABT, Senior Director of Toxicology, Toxicology Department, Johnson and Johnson
PRD, L.L.C.
Panelists:
Patricia Turney, Director, R&D Strategic Operations, Amgen, Inc.
Romi Singh, Ph.D., Director, Global Strategic Regulatory Development,
Merck & Co., Inc.
Ramana Sonty, Ph.D., Senior Director, Global Project Management Worldwide Development, Pfizer Inc.
Dilip Mehta, M.D., Ph.D., former Senior Vice President, US
Clinical Research, Pfizer Inc.
|
|
|
3:00 The Evolution of Merck’s Lab Scale Chemistry Efforts in India
• Merck’s entrance into lab scale sourcing in India
• Review of past challenges and lessons learned
• Current strategy towards sourcing in the emerging market
Bryan Kraker, Global Basic and PreClinical Sourcing, Merck & Co., Inc.
|
3:30 Afternoon Refreshment Break
(Sponsorship Available)
|
|
4:00 Building a Veterinary Medicine Pharmaceutical Sciences Function in India
This presentation will describe strategy and tactics associated with building a Pharmaceutical Sciences group to develop and enhance new chemical entities in India.
James Freeman, Ph.D., Vice President Laboratory Sciences, Pfizer Global R&D
|
|
|
4:30 Challenges That Have Limited India’s Drug Discovery & Development Potential:
“From Dead Ends to Tipping Point”
This discussion will look at India’s challenges through various lenses (e.g., balancing generics and NCE businesses; IP; funding; government/policy; education/talent; reimbursement; etc.) and attempt to address the following questions:
• How have challenges changed over time? How were they overcome (mini case
studies)?
• What are the current challenges? What are the new, expected challenges likely
to be?
• What will propel India past the “tipping point” and truly unleash its drug
discovery and development potential?
Amit Patel, Vice President, Corporate Development & Strategic Planning,
Dr. Reddy’s Laboratories, Inc.
|
5:00 Close of Executive
Forum
* Times, speakers, and topics are subject to change.
|
